Q-omics provides the consensus-scored H3C6 profile across patient tissues and cancer cell-line models. H3C6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, H3C6 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, H3C6 RNA expression shows 18,699 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where H3C6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H3C6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H3C6 survival associations across molecular data types. H3C6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H3C6 RNA expression–survival associations across cancer types. High H3C6 expression shows unfavorable associations in COAD, ACC, LGG and HNSC, but favorable associations in KIRC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for H3C6 RNA expression.
This table summarizes H3C6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for H3C6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H3C6 shows lower tumor expression in THCA and higher tumor expression in KIRC, LIHC, LUSC, LUAD and HNSC. The KIRC box plot shows higher H3C6 RNA expression in tumor versus normal tissue (log2 FC = +0.923, t-test p < 0.001).
This table shows molecular features associated with H3C6 in patient tissues and cancer cell lines. In patient samples, H3C6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, H3C6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
